HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients

British Journal of Cancer

Volumn 111, Issue 6, 2014, Pages 1080-1088

  Zhao, X Y ^a   Chang, Y J ^a   Xu, L P ^a   Zhang, X H ^a   Liu, K Y ^a   Li, D ^a   Huang, X J ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Tsinghua University   (China)

Author keywords

CML; haploidentical; HSCT; KIR

Indexed keywords

HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; HLA BW4 ANTIGEN; HLA C*01:02 ANTIGEN; HLA C*02 ANTIGEN; HLA-BW4 ANTIGEN; HLA-C*01:02 ANTIGEN; HLA-C*02 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; KIR2DS1 PROTEIN, HUMAN; LIGAND;

ADULT; ARTICLE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; DONOR LYMPHOCYTE INFUSION; DONOR SELECTION; FEMALE; GENE ACTIVATION; GENE FREQUENCY; GENOTYPE; HAPLOIDY; HAPLOTYPE; HEMATOPOIETIC STEM CELL; HLA TYPING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; STEM CELL TRANSPLANTATION; T CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION; T LYMPHOCYTE; THROMBOCYTE COUNT; ADOLESCENT; CHILD; DISEASE FREE SURVIVAL; GENETICS; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE; SURVIVAL RATE; TRANSPLANTATION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DISEASE-FREE SURVIVAL; DONOR SELECTION; FEMALE; GENOTYPE; GRAFT VS HOST DISEASE; HAPLOIDY; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIGANDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, KIR; RECEPTORS, KIR3DS1; RECURRENCE; SURVIVAL RATE; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84908390745     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.423     Document Type: Article

References (34)

1. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B (2007) KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 179: 854-868.
2. Fuchs EJ, Huang XJ, Miller JS (2010) HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 16: S57-S63.
3. Gabriel IH, Sergeant R, Szydlo R, Apperley JF, deLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, Davis J, MacDonald D, Bua M, Foroni L, Giles C, Milojkovic D, Rahemtulla A, Rezvani K (2010) Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood 116: 2033-2039.
4. Huang XJ (2008) Current status of haploidentical stem cell transplantation for leukemia. J Hematol Oncol 1: 27.
5. Huang XJ, Zhao X.Y, Liu DH, Liu KY, Xu LP (2007) Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 21: 848-851.
6. Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ (2011) Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 117: 3032-3040.
7. Kijima M, Gardiol N, Held W (2011) Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo. PLoS One 6: e27639.
8. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.
9. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, Houston J, Handgretinger R (2005) Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174: 6540-6545.
10. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R (2004) Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172: 644-650.
11. Marcenaro E, Carlomagno S, Pesce S, Della Chiesa M, Moretta A, Sivori S (2011) Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation. J Leukocyte Biol 90: 661-667.
12. Marcenaro E, Pesce S, Sivori S, Carlomagno S, Moretta L, Moretta A (2013) KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DC or T cell blasts. Blood 121: 3396-3401.
13. Pfeiffer MM, Feuchtinger T, Teltschik HM, Schumm M, Muller I, Handgretinger R, Lang P (2010) Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. Haematologica 95: 1381-1388.
14. Pittari G, Liu X-R, Selvakumar A, Zhao Z, Merino E, Huse M, Chewning JH, Hsu KC, Dupont B (2013) NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand. J Immunol 190: 4650-4660.
15. Raulet DH, Vance RE (2006) Self-tolerance of natural killer cells. Nat Rev Immunol 6: 520-531.
16. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94: 333-339.
17. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
18. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A (2007) Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110: 433-440.
19. Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM, Nadal E, Bua M, Rahemtulla A, Kanfer E, Marin D, Olavarria E, Goldman JM, Apperley JF, Dazzi F (2007) Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia 21: 943-948.
20. Sivori S, Carlomagno S, Falco M, Romeo E, Moretta L, Moretta A (2011) Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 117: 4284-4292.
21. Sun JC, Beilke JN, Lanier LL (2009) Adaptive immune features of natural killer cells. Nature 457: 557-561.
22. Sungur CM, Tang-Feldman YJ, Zamora AE, Alvarez M, Pomeroy C, Murphy WJ (2013) Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. Blood 122: 1518-1521.
23. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ (2010) Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 16: 533-542.
24. Tripathy SK, Keyel PA, Yang L, Pingel JT, Cheng TP, Schneeberger A, Yokoyama WM (2008) Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J Exp Med 205: 1829-1841.
25. Triplett BM, Horwitz EM, Iyengar R, Turner V, Holladay MS, Gan K, Behm FG, Leung W (2009) Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia 23: 1278-1287.
26. Vago L, Forno B, Sormani MP, Crocchiolo R, Zino E, Di Terlizzi S, Lupo Stanghellini MT, Mazzi B, Perna SK, Bondanza A, Middleton D, Palini A, Bernardi M, Bacchetta R, Peccatori J, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K (2008) Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 112: 3488-3499.
27. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC (2012) HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367: 805-816.
28. Xiao-jun H, Lan-ping X, Kai-yan L, Dai-hong L, Huan C, Wei H, Yu-hong C, Jing-zhi W, Yao C, Xiao-hui Z, Hong-Xia S, Dao-Pei L (2008) HLAmismatched/haploidentical hematopoietic stem cell transplantation withoutin vitroT cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 40: 444-455.
29. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P (2006) Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 203: 633-645.
30. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P (2008) MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing selfresponse. Blood 112: 2369-2380.
31. Yong AS, Keyvanfar K, Hensel N, Eniafe R, Savani BN, Berg M, Lundqvist A, Adams S, Sloand EM, Goldman JM, Childs R, Barrett AJ (2009) Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113: 875-882.
32. Yu J, Heller G, Chewning J, Kim S, Yokoyama W.M, Hsu KC (2007) Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 179: 5977-5989.
33. Zhao XY, Chang YJ, Huang XJ (2011) Conflicting impact of alloreactive NK cells on transplantation outcomes after haploidentical transplantation: do the reconstitution kinetics of natural killer cells create these differences? Biol Blood Marrow Transplant 17: 1436-1442.
34. Zhao XY, Huang XJ, Liu KY, Xu LP, Liu DH (2007) Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Eur J Haematol 78: 338-346.